Core Insights - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. reported a steady growth in revenue and an optimized business structure in its Q3 2025 report, indicating a solid foundation for future development [1][2][3] Revenue Performance - In Q3 2025, the company achieved a revenue of 1.085 billion yuan, representing a year-on-year increase of 7.41% [1] - Cumulative revenue for the year reached 3.242 billion yuan, showing growth compared to the previous year [1] - The company demonstrated strong operational resilience amidst intensified competition in the pharmaceutical distribution industry [1] Supply Chain and Business Optimization - The company's accounts payable increased by 81.37% compared to the end of the previous year, enhancing capital efficiency and supplier collaboration [2] - Construction of new non-pharmaceutical production lines surged by 360.77%, diversifying product offerings and expanding growth points [2] Investment and Financial Performance - Long-term equity investments grew by 112.16%, with new investments in affiliated companies, expanding the business landscape in the healthcare sector [2] - Investment income saw a significant increase of 300.24% year-on-year, contributing positively to overall performance [2] Cost Management and Subsidiary Development - Despite an increase in sales expenses due to e-commerce expansion, subsidiaries showed significant profit growth, leading to a 39.38% rise in tax liabilities compared to the previous year [2] Future Outlook - The company plans to continue leveraging its pharmaceutical distribution advantages, deepen supply chain strengths, accelerate non-pharmaceutical production line development, and pursue innovative business expansion for higher quality growth [3]